Cargando…

Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN

Squamous cell lung carcinoma (SCC) accounts for 30% of patients with NSCLC and to date, no molecular targeted agents are approved for this type of tumor. However, recent studies have revealed several oncogenic mutations in SCC patients, including an alteration of the PI3K/AKT pathway, i.e. PI3K poin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cavazzoni, Andrea, La Monica, Silvia, Alfieri, Roberta, Ravelli, Andrea, Van Der Steen, Nele, Sciarrillo, Rocco, Madeddu, Denise, Lagrasta, Costanza Anna Maria, Quaini, Federico, Bonelli, Mara, Fumarola, Claudia, Cretella, Daniele, Digiacomo, Graziana, Tiseo, Marcello, Peters, Godefridus J., Ardizzoni, Andrea, Petronini, Pier Giorgio, Giovannetti, Elisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581093/ https://www.ncbi.nlm.nih.gov/pubmed/28881794 http://dx.doi.org/10.18632/oncotarget.18087

Ejemplares similares

Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism
por: Fumarola, Claudia, et al.
Publicado: (2017)

Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC
por: La Monica, Silvia, et al.
Publicado: (2019)

Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer
por: Cavazzoni, Andrea, et al.
Publicado: (2020)

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance
por: Cretella, Daniele, et al.
Publicado: (2014)

The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells
por: Cretella, Daniele, et al.
Publicado: (2018)

Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells()
por: Bonelli, Mara A., et al.
Publicado: (2017)

PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition
por: Cretella, Daniele, et al.
Publicado: (2019)

Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells
por: Cretella, Daniele, et al.
Publicado: (2019)

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
por: La Monica, Silvia, et al.
Publicado: (2017)

Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib
por: La Monica, Silvia, et al.
Publicado: (2020)

Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells
por: Bonelli, Mara, et al.
Publicado: (2020)

Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines
por: Digiacomo, Graziana, et al.
Publicado: (2020)

Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
por: Cavazzoni, Andrea, et al.
Publicado: (2012)

Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with MET Amplification
por: La Monica, Silvia, et al.
Publicado: (2013)

Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines
por: Galetti, Maricla, et al.
Publicado: (2015)

New Treatment Opportunities in Phosphatase and Tensin Homolog (PTEN)-Deficient Tumors: Focus on PTEN/Focal Adhesion Kinase Pathway
por: Alfieri, Roberta, et al.
Publicado: (2017)

CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells
por: Terenziani, Rita, et al.
Publicado: (2022)

CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells
por: Digiacomo, Graziana, et al.
Publicado: (2022)

Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method
por: Bozzetti, Cecilia, et al.
Publicado: (2015)

Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines
por: Fumarola, Claudia, et al.
Publicado: (2019)

Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines
por: Alfieri, Roberta R, et al.
Publicado: (2011)

Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators
por: Volta, Francesco, et al.
Publicado: (2023)

Role of Cytokines and Other Soluble Factors in Tumor Development: Rationale for New Therapeutic Strategies
por: Cavazzoni, Andrea, et al.
Publicado: (2023)

YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs
por: Minari, Roberta, et al.
Publicado: (2022)

Hypertonic Stress and Amino Acid Deprivation Both Increase Expression of mRNA for Amino Acid Transport System A
por: Alfieri, Roberta R., et al.
Publicado: (2005)

Biological Hallmarks and New Therapeutic Approaches for the Treatment of PDAC
por: Digiacomo, Graziana, et al.
Publicado: (2021)

MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report()()
por: Rihawi, Karim, et al.
Publicado: (2018)

It Takes Two to Tango: Potential Prognostic Impact of Circulating TGF-Beta and PD-L1 in Pancreatic Cancer
por: Garajová, Ingrid, et al.
Publicado: (2022)

Clinico-Immunological Profile of a 67-Year-Old Woman Affected by HER2-Positive Breast Cancer and Autoimmune Dermatomyositis
por: Pellegrino, Benedetta, et al.
Publicado: (2020)

PTEN status in advanced colorectal cancer treated with cetuximab
por: Negri, F V, et al.
Publicado: (2010)

Development of Biomimetic Alginate/Gelatin/Elastin Sponges with Recognition Properties toward Bioactive Peptides for Cardiac Tissue Engineering
por: Rosellini, Elisabetta, et al.
Publicado: (2020)

Integrated MRI–Immune–Genomic Features Enclose a Risk Stratification Model in Patients Affected by Glioblastoma
por: Mazzaschi, Giulia, et al.
Publicado: (2022)

Isolation and Characterization of Human Lung Lymphatic Endothelial Cells
por: Lorusso, Bruno, et al.
Publicado: (2015)

Dataset on the identification of a prognostic radio-immune signature in surgically resected Non Small Cell Lung Cancer
por: Mazzaschi, Giulia, et al.
Publicado: (2020)

Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer
por: Eltayeb, Kamal, et al.
Publicado: (2022)

Immunotherapeutic Approaches in Malignant Pleural Mesothelioma
por: Terenziani, Rita, et al.
Publicado: (2021)

Shc and Fak Differentially Regulate Cell Motility and Directionality Modulated by Pten
por: Gu, Jianguo, et al.
Publicado: (1999)

New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?
por: Van Der Steen, Nele, et al.
Publicado: (2016)

Parenchymal and Stromal Cells Contribute to Pro-Inflammatory Myocardial Environment at Early Stages of Diabetes: Protective Role of Resveratrol
por: Savi, Monia, et al.
Publicado: (2016)

Transforming Growth Factor-Beta Signaling in Cancer-Induced Cachexia: From Molecular Pathways to the Clinics
por: Balsano, Rita, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ncas3o1tchegi3hlnk20rpd3p6